<DOC>
	<DOCNO>NCT02243137</DOCNO>
	<brief_summary>This phase I clinical trial healthy volunteer compare effect lysine acetylsalicylate aspirin platelet function .</brief_summary>
	<brief_title>Study Platelet Function After Administration Aspirin Versus Lysine Acetylsalicylate</brief_title>
	<detailed_description>1 . SUMMARY 1.1 . Type trial Phase I clinical trial healthy volunteer market drug 1.2 . Identification promoter ( correspondence ) Dr. David Vivas Balcones Cardiology Department Hospital Clínico San Carlos C/Prof Martín Lagos SN 28040 Madrid Phone : +34 91 330 31 49 Fax : +34 913303142 Email : dvivas @ secardiologia.es 1.3 . Clinical trial title Effect combine administration prasugrel lysine acetylsalicylate intravenously versus prasugrel aspirin platelet aggregation healthy volunteer ( ECCLIPSE trial ) . 1.4 . Protocol code Nº EudraCT : 2012-001702-20 Code : 2012-ECCLIPSE-01 Version : V3 Date : 13/04/2012 1.5 . Project principal investigator Dr. David Vivas Balcones Cardiology Department Hospital Clínico San Carlos C/Prof Martín Lagos SN 28040 Madrid Phone : +34 91 330 31 49 Fax : +34 913303142 Email : dvivas @ secardiologia.es 1.6 . Centers Investigators San Carlos University Hospital ( Madrid ) . Within follow service researcher involve : Cardiology Department Hospital Clínico San Carlos C/Prof Martín Lagos SN 28040 Madrid Teléfono : +34 91 330 31 49 Fax : +34 913303142 Project principal investigator Promoter : Dr. David Vivas Balcones Co-Investigators : Dr. Agustín Martín , Dr. Isidre Vilacosta , Dr. Iván Núñez-Gil Dr. Carlos Macaya Platelet function laboratory Cardiology Department Hospital Clínico San Carlos C/Prof Martín Lagos SN 28040 Madrid Phone : +34 913307260 Fax : +34 913303142 Co-Investigators : Dr. Antonio Fernández-Ortiz , Esther Bernardo María Aranzazu Ortega Pozzi Clinical Trials Unit ( CEIC ) Biomedical Research Foundation Hospital Clínico San Carlos C/ Prof. Martín Lagos S/N 28040 Madrid Phone : + 34 913303793 Fax : +34 913303515 Co-Investigator : Dra . Saioa Alonso Clinical Research Ethics Committee The Clinical Research Ethics Committee ( CEIC ) charge assess project CEIC San Carlos University Hospital . 1.7 . Responsible Monitoring : MEDITRIALS 1.8 . Experimental control drug • Experimental group : Loading dose ( LD ) intravenous lysine acetylsalicylate 450 mg prasugrel 60 mg orally . • Control group : Loading dose ( LD ) aspirin 300 mg orally prasugrel 60 mg orally . Being crossover study , subject receive treatment arm two treatment period gap 15 day ( washout period ) two administration . 1.9 . Study endpoint Primary endpoint To compare inhibition platelet aggregation ( IPA ) 30 minute administration prasugrel load dose association intravenous lysine acetylsalicylate versus prasugrel plus aspirin . Secundary endpoint To compare inhibition platelet aggregation ( IPA ) 0 ( baseline ) , 1 , 4 24 hour administration treatment group . To compare inhibition platelet reactivity ( IPR ) throughout time period treatment group . To evaluate safety treatment administer . 1.10 . Study design The ECCLIPSE study phase I , randomize , single center , open , two-period crossover trial subject receive single dose certain drug treatment group . 1.11 . Pathology study None . 1.12 . Population sample size The study population healthy volunteer ( total 30 subject ) . This pharmacodynamic study , subsequent extrapolation finding patient acute coronary syndrome 1.13 . Duration treatment In period treatment , subject receive single dose drug determine treatment arm analysis parameter study process next 24 hour . After two week washout period , subject receive study drug regimen single dose take place analysis within 24 hour parameter study . 1.14 . Primary variable Inhibition platelet aggregation measure light transmission aggregometry 30 minute .</detailed_description>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Acetylsalicylic acid lysinate</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<criteria>Age 1860 year . BMI &gt; 19kg/m2 &lt; 29kg/m2 . Women childbearing potential commit use medically effective contraception participation study , except hormonal contraceptive . Percentage inhibition platelet aggregation stimulation high basal 20 mM ADP arachidonic acid 1.5 mM &gt; 70 % . No clinically significant deviation physical examination , ECG laboratory value laboratory test . Signed informed consent Smoking Drug abuse Pregnant lactate Infection Hepatitis B C , HIV Known drug allergy Family history blood disorder coagulation . History disease alters absorption , metabolism excretion drug , include jaundice . Personal history bleed / blood dyscrasia ( especially hemophilia , hypoprothrombinemia ) , include vascular malformation reasonable suspicion . History medically relevant condition Background major surgery last 3 month Prescription chronic medication 14 day prior study participation . Participation another study involve administration investigational product last 4 month product already market last three month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>